NCT03860272 2025-02-06Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerAgenus Inc.Phase 1 Active not recruiting499 enrolled
NCT06751524 2024-12-30Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalAgenus Inc.Available